BioMarin Passes $1 Billion In Quarterly Revenue, Then Cuts Its 2026 Profit Outlook To $2.80-$3.10 A Share
The rare-disease drugmaker cut its full-year adjusted EPS forecast from $4.90-$5.10 after two acquired-research charges and a delayed international order.
BioMarin Pharmaceutical, which develops medicines for rare genetic diseases, said Monday that third-quarter revenue topped $1 billion for the first time, reaching $1.025 billion, up 32% from a year earlier. It also lowered its 2026 adjusted earnings guidance to $2.80 to $3.10 per share, from $4.90 to $5.10.
Amicus drugs drive the growth
The two products BioMarin acquired from Amicus Therapeutics on April 27, 2026 supplied much of the jump. GALAFOLD brought in $152 million and POMBILITI + OPFOLDA $49 million in what the company called their first full quarter under BioMarin.
Metabolic Conditions revenue rose 44% to $744 million, while VOXZOGO, the achondroplasia drug, grew 12% to $245 million. Patients on VOXZOGO rose 17% and NAGLAZYME sales fell 11% on the timing of large international orders.
CEO Alexander Hardy called it "a strong quarter" and said the company is building on it through business development.
A loss on deal costs, a lower outlook
BioMarin posted a GAAP net loss of $123 million, or $0.63 a share, against a $31 million loss a year earlier. The company cited Amicus costs, including intangible amortization, interest on acquisition debt, inventory step-up and integration charges, plus acquired research charges tied to its Alesta Therapeutics purchase. Adjusted income rose to $45 million from $22 million.
On guidance, the company expects Alesta and a license for the Fabry asset BMN 450 to cost about $320 million and $83 million pre-tax in 2026. That is an unfavorable impact of about $1.55 and $0.32 a share. Full-year revenue guidance moved to $3.8 billion to $3.9 billion from $3.875 billion to $3.925 billion, because a large international VOXZOGO order once expected in the third quarter is now anticipated in the fourth.
More debt, less cash
Long-term debt stood at $3.51 billion at the end of September, with another $659 million due within a year, against $597 million at the end of 2025. Cash and equivalents fell to $736 million from $1.31 billion. BioMarin still expects about $280 million of cost savings from the Amicus deal on a standard accounting basis, fully realized in 2028.
The FDA has a target action date of February 28, 2027 on full approval of VOXZOGO in children with achondroplasia, and May 30, 2027 on its use in hypochondroplasia.
The FDA's February 28, 2027 target date for full VOXZOGO approval in achondroplasia is the next dated test for the drug behind BioMarin's skeletal business.
Sources
- 8-K Filing — BIOMARIN PHARMACEUTICAL INC (BMRN) — SEC EDGAR
- Exhibit earningsrelease-2nov26ex991.htm — BIOMARIN PHARMACEUTICAL INC 8-K exhibit — SEC EDGAR
- BioMarin Reports Third Quarter 2026 Financial and Operating Results — Yahoo Finance